Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.41 |
| ▸ | PDE4B | Q07343 | 8/20 | 0.36 |
| ▸ | PDE4A | P27815 | 7/20 | 0.36 |
| ▸ | PDE4C | Q08493 | 7/20 | 0.36 |
| ▸ | PDE4D | Q08499 | 7/20 | 0.36 |
| ▸ | ACHE | P22303 | 3/20 | 0.36 |
| ▸ | BCHE | P06276 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.32 |
| ▸ | HTT | P42858 | 1/20 | 0.32 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.32 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.32 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.32 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.31 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | NPC1 | O15118 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6601910 | 1.00 | LMNA (0.41) | LMNAALDH1A1KDM4EHSD17B10PDE4B | |
| SCHEMBL6601911 | 1.00 | LMNA (0.41) | LMNAALDH1A1KDM4EHSD17B10PDE4B | |
| SCHEMBL6607854 | 0.86 | PDE4B (0.53) | LMNAALDH1A1KDM4EHSD17B10PDE4B | |
| SCHEMBL4958570 | 0.86 | PDE4B (0.53) | LMNAALDH1A1KDM4EHSD17B10PDE4B | |
| SCHEMBL6607847 | 0.86 | PDE4B (0.53) | LMNAALDH1A1KDM4EHSD17B10PDE4B | |
| SCHEMBL29357646 | 0.86 | PDE4B (0.53) | LMNAALDH1A1KDM4EHSD17B10PDE4B | |
| SCHEMBL6602221 | 0.85 | KDM4E (0.42) | LMNAALDH1A1KDM4EHSD17B10PDE4B | |
| SCHEMBL6602217 | 0.85 | KDM4E (0.42) | LMNAALDH1A1KDM4EHSD17B10PDE4B | |
| SCHEMBL6602224 | 0.85 | KDM4E (0.42) | LMNAALDH1A1KDM4EHSD17B10PDE4B | |
| SCHEMBL14473028 | 0.84 | LMNA (0.39) | LMNAALDH1A1KDM4EHSD17B10PDE4B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1110961-B1 | OXYGENIC HETEROCYCLIC COMPOUNDS | KYOWA HAKKO KOGYO KK (JP) | 2004-07-14 | — | — | EP | disclosed |
| US-20030100772-A1 | Oxygen-containing heterocyclic compounds | KYOWA HAKKO KOGYO CO., LTD. (JP) | 2003-05-29 | — | — | US | disclosed |
| EP-1264829-A1 | OXYGEN-CONTAINING HETEROCYCLIC COMPOUNDS | KYOWA HAKKO KOGYO CO., LTD. (JP) | 2002-12-11 | — | — | EP | disclosed |
| US-6376535-B2 | PHOSPHODIESTERASE (PDE) INHIBITOR | KYOWA HAKKO KOGYO CO., LTD. (JP) | 2002-04-23 | — | — | US | disclosed |
| US-20010056117-A1 | Oxygen-containing heterocyclic compounds | KYOWA HAKKO KIRIN CO., LTD. (JP) | 2001-12-27 | — | — | US | disclosed |
| EP-1110961-A1 | OXYGENIC HETEROCYCLIC COMPOUNDS | KYOWA HAKKO KOGYO CO., LTD. (JP) | 2001-06-27 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010056117-A1 | Oxygen-containing heterocyclic compounds | CBR1, CBR3, MT-CO1 | LMNA 4242/4885ALDH1A1 232/4885KDM4E 444/4885 |
| US-20030100772-A1 | Oxygen-containing heterocyclic compounds | CBR1, CYP11B2, CBR3 | LMNA 4580/4885ALDH1A1 263/4885KDM4E 1212/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.